{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:22Z","timestamp":1786980262382,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006942","name":"Medical University of South Carolina","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006942","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a lack of evidence to suggest that outcomes of adolescent and adult-onset glomerular disease differ. Still, most glomerular disease trials include adults but exclude adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We designed a retrospective study using the CureGN database to compare individuals with adolescent-onset glomerular disease relative to individuals with older and younger age at onset. The two main outcomes were sustained proteinuria remission off immunosuppression treatment and composite eGFR decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our data did not show a significant difference in sustained proteinuria remission off treatment or composite eGFR decline between adolescent onset glomerular disease and either childhood (age 5\u201312), young adult (age 20\u201329), or adult (age 30\u201339) onset glomerular disease. Having high-risk\n                      <jats:italic>APOL1<\/jats:italic>\n                      alleles and hypertension at the time of study enrollment decreased the likelihood of achieving sustained proteinuria remission off treatment. While participants with minimal change disease and IgA nephropathy were similarly likely to achieve sustained proteinuria remission off treatment, participants with focal segmental glomerulosclerosis and membranous nephropathy were less likely to achieve sustained proteinuria remission off treatment compared to participants with minimal change disease. CKD stage, high-risk\n                      <jats:italic>APOL1<\/jats:italic>\n                      alleles, hypertension stage, and education all significantly impacted the likelihood of progression to the composite eGFR decline outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 25% of each age cohort reached the composite eGFR decline outcome within 5\u00a0years. As more glomerular disease clinical trials become available, we must consider opening these trials to people with childhood and adolescent onset disease since like adults they are at high risk of progressive kidney function decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-024-06566-4","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:05:37Z","timestamp":1735257937000},"page":"1949-1958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-0099","authenticated-orcid":false,"given":"Kelly","family":"Garrity","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Putnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Massengill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myda","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"6566_CR1","doi-asserted-by":"publisher","first-page":"c161","DOI":"10.1159\/000145460","volume":"109","author":"LR Requi\u00e3o-Moura","year":"2008","unstructured":"Requi\u00e3o-Moura LR, Veras de S. Freitas T, Franco MF et al (2008) Should adolescents with glomerulopathies be treated as children or adults? Nephron Clin Pract 109:c161\u2013c167. https:\/\/doi.org\/10.1159\/000145460","journal-title":"Nephron Clin Pract"},{"key":"6566_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.4.5627.352","volume":"4","author":"JS Cameron","year":"1968","unstructured":"Cameron JS (1968) Histology, protein clearances, and response to treatment in the nephrotic syndrome. Br Med J 4:352\u2013356. https:\/\/doi.org\/10.1136\/bmj.4.5627.352","journal-title":"Br Med J"},{"key":"6566_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s004670050555","volume":"13","author":"T Srivastava","year":"1999","unstructured":"Srivastava T, Simon SD, Alon US (1999) High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13:13\u201318. https:\/\/doi.org\/10.1007\/s004670050555","journal-title":"Pediatr Nephrol"},{"key":"6566_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","volume":"21","author":"DS Gipson","year":"2006","unstructured":"Gipson DS, Chin H, Presler TP et al (2006) Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21:344\u2013349. https:\/\/doi.org\/10.1007\/s00467-005-2097-0","journal-title":"Pediatr Nephrol"},{"key":"6566_CR5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s00467-006-0163-x","volume":"21","author":"J Ronkainen","year":"2006","unstructured":"Ronkainen J, Ala-Houhala M, Autio-Harmainen H et al (2006) Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 21:1266\u20131273. https:\/\/doi.org\/10.1007\/s00467-006-0163-x","journal-title":"Pediatr Nephrol"},{"key":"6566_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/ndt\/gfn014","volume":"23","author":"M Haas","year":"2008","unstructured":"Haas M, Rahman MH, Cohn RA et al (2008) IgA Nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant 23:2537\u20132545. https:\/\/doi.org\/10.1093\/ndt\/gfn014","journal-title":"Nephrol Dial Transplant"},{"key":"6566_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00467-006-0301-5","volume":"22","author":"KH Paik","year":"2007","unstructured":"Paik KH, Lee BH, Cho HY et al (2007) Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol 22:389\u2013395. https:\/\/doi.org\/10.1007\/s00467-006-0301-5","journal-title":"Pediatr Nephrol"},{"key":"6566_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2369-8-11","volume":"8","author":"A Chen","year":"2007","unstructured":"Chen A, Frank R, Vento S et al (2007) Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol 8:11. https:\/\/doi.org\/10.1186\/1471-2369-8-11","journal-title":"BMC Nephrol"},{"key":"6566_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40620-020-00816-y","volume":"34","author":"R Wang","year":"2021","unstructured":"Wang R, Wang M, Xia Z et al (2021) Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: a retrospective analysis of 217 cases. J Nephrol 34:589\u2013596. https:\/\/doi.org\/10.1007\/s40620-020-00816-y","journal-title":"J Nephrol"},{"key":"6566_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00467-023-06210-7","volume":"39","author":"HS Kim","year":"2024","unstructured":"Kim HS, Ng DK, Matheson MB et al (2024) Pubertal luteinizing hormone levels in children with chronic kidney disease and association with change in glomerular filtration rate. Pediatr Nephrol 39:1543\u20131549. https:\/\/doi.org\/10.1007\/s00467-023-06210-7","journal-title":"Pediatr Nephrol"},{"key":"6566_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","volume":"23","author":"A Denic","year":"2016","unstructured":"Denic A, Glassock RJ, Rule AD (2016) Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis 23:19\u201328. https:\/\/doi.org\/10.1053\/j.ackd.2015.08.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"6566_CR12","doi-asserted-by":"publisher","first-page":"e004481","DOI":"10.1136\/rmdopen-2024-004481","volume":"10","author":"C Barnini","year":"2024","unstructured":"Barnini C, Oni L, Kronbichler A (2024) Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach. RMD Open 10:e004481. https:\/\/doi.org\/10.1136\/rmdopen-2024-004481","journal-title":"RMD Open"},{"key":"6566_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000535955","volume":"4","author":"D Garrisi","year":"2024","unstructured":"Garrisi D, Bevan A, Angeles C (2024) Advancing treatments for rare renal diseases: new hopes and opportunities to address a high unmet need. Glomerular Dis 4:11\u201318. https:\/\/doi.org\/10.1159\/000535955","journal-title":"Glomerular Dis"},{"key":"6566_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/0886022X.2022.2048017","volume":"44","author":"Y Cui","year":"2022","unstructured":"Cui Y, Zhai Y-L, Qi Y-Y et al (2022) The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov. Ren Fail 44:461\u2013472. https:\/\/doi.org\/10.1080\/0886022X.2022.2048017","journal-title":"Ren Fail"},{"key":"6566_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B et al (2023) Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18:727\u2013738. https:\/\/doi.org\/10.2215\/CJN.0000000000000135","journal-title":"Clin J Am Soc Nephrol"},{"key":"6566_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.ajkd.2018.07.020","volume":"73","author":"LH Mariani","year":"2019","unstructured":"Mariani LH, Bomback AS, Canetta PA et al (2019) CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease. Am J Kidney Dis 73:218\u2013229. https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.020","journal-title":"Am J Kidney Dis"},{"key":"6566_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1258\/acb.2009.009007","volume":"46","author":"EJ Lamb","year":"2009","unstructured":"Lamb EJ, MacKenzie F, Stevens PE (2009) How should proteinuria be detected and measured? Ann Clin Biochem 46:205\u2013217. https:\/\/doi.org\/10.1258\/acb.2009.009007","journal-title":"Ann Clin Biochem"},{"key":"6566_CR18","doi-asserted-by":"publisher","first-page":"854300","DOI":"10.3389\/fmed.2022.854300","volume":"9","author":"X Qin","year":"2022","unstructured":"Qin X, Hu H, Cen J et al (2022) Association between urinary protein-to-creatinine ratio and chronic kidney disease progression: a secondary analysis of a prospective cohort study. Front Med 9:854300. https:\/\/doi.org\/10.3389\/fmed.2022.854300","journal-title":"Front Med"},{"key":"6566_CR19","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00467-022-05429-0","volume":"37","author":"H Pottel","year":"2022","unstructured":"Pottel H, Bj\u00f6rk J, Delanaye P, Nyman U (2022) Evaluation of the creatinine-based chronic kidney disease in children (under 25 years) equation in healthy children and adolescents. Pediatr Nephrol 37:2213\u20132216. https:\/\/doi.org\/10.1007\/s00467-022-05429-0","journal-title":"Pediatr Nephrol"},{"key":"6566_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/clinchem\/hvab282","volume":"68","author":"JW Meeusen","year":"2022","unstructured":"Meeusen JW, Kasozi RN, Larson TS, Lieske JC (2022) Clinical impact of the refit CKD-EPI 2021 creatinine-based eGFR equation. Clin Chem 68:534\u2013539. https:\/\/doi.org\/10.1093\/clinchem\/hvab282","journal-title":"Clin Chem"},{"key":"6566_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"G-Z Yu","year":"2020","unstructured":"Yu G-Z, Guo L, Dong J-F et al (2020) Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis 76:90\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008","journal-title":"Am J Kidney Dis"},{"key":"6566_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10157-013-0849-x","volume":"18","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Matsuzaki K, Suzuki H et al (2014) Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol 18:481\u2013486. https:\/\/doi.org\/10.1007\/s10157-013-0849-x","journal-title":"Clin Exp Nephrol"},{"key":"6566_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/ndt\/gfv269","volume":"31","author":"SV Badve","year":"2016","unstructured":"Badve SV, Palmer SC, Hawley CM et al (2016) Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrol Dial Transplant 31:1425\u20131436. https:\/\/doi.org\/10.1093\/ndt\/gfv269","journal-title":"Nephrol Dial Transplant"},{"key":"6566_CR24","doi-asserted-by":"publisher","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","volume":"140","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904. https:\/\/doi.org\/10.1542\/peds.2017-1904","journal-title":"Pediatrics"},{"key":"6566_CR25","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13\u2013e115. https:\/\/doi.org\/10.1161\/HYP.0000000000000065","journal-title":"Hypertension"},{"key":"6566_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.ackd.2014.06.005","volume":"21","author":"S Limou","year":"2014","unstructured":"Limou S, Nelson GW, Kopp JB, Winkler CA (2014) APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 21:426\u2013433. https:\/\/doi.org\/10.1053\/j.ackd.2014.06.005","journal-title":"Adv Chronic Kidney Dis"},{"key":"6566_CR27","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038. https:\/\/doi.org\/10.1001\/jama.298.17.2038","journal-title":"JAMA"},{"key":"6566_CR28","unstructured":"America\u2019s health literacy: why we need accessible health information. An Issue Brief From the U.S. Department of Health and Human Services. 2008.\u00a0https:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/health-literacy\/dhhs-2008-issue-brief.pdf"},{"key":"6566_CR29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/s41390-023-02608-z","volume":"94","author":"E Nash","year":"2023","unstructured":"Nash E, Bickerstaff M, Chetwynd AJ et al (2023) The readability of parent information leaflets in paediatric studies. Pediatr Res 94:1166\u20131171. https:\/\/doi.org\/10.1038\/s41390-023-02608-z","journal-title":"Pediatr Res"},{"key":"6566_CR30","doi-asserted-by":"publisher","first-page":"1175088","DOI":"10.3389\/fneph.2023.1175088","volume":"3","author":"SM Noor","year":"2023","unstructured":"Noor SM, Abuazzam F, Mathew R et al (2023) IgA nephropathy: a review of existing and emerging therapies. Front Nephrol 3:1175088. https:\/\/doi.org\/10.3389\/fneph.2023.1175088","journal-title":"Front Nephrol"},{"key":"6566_CR31","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI (2022) Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep 7:1463\u20131476. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094","journal-title":"Kidney Int Rep"},{"key":"6566_CR32","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/jcm11102810","volume":"11","author":"D Maixnerova","year":"2022","unstructured":"Maixnerova D, El Mehdi D, Rizk DV et al (2022) New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. J Clin Med 11:2810. https:\/\/doi.org\/10.3390\/jcm11102810","journal-title":"J Clin Med"},{"key":"6566_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V et al (2024) Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105:189\u2013199. https:\/\/doi.org\/10.1016\/j.kint.2023.09.027","journal-title":"Kidney Int"},{"key":"6566_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","unstructured":"EMPA-KIDNEY Collaborative Group (2024) Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 12:51\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(23)00322-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6566_CR35","doi-asserted-by":"publisher","first-page":"e004315","DOI":"10.1136\/rmdopen-2024-004315","volume":"10","author":"SK Mann","year":"2024","unstructured":"Mann SK, Bone JN, Bosman ES et al (2024) Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis. RMD Open 10:e004315. https:\/\/doi.org\/10.1136\/rmdopen-2024-004315","journal-title":"RMD Open"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06566-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:55:35Z","timestamp":1745560535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06566-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6566"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06566-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}